Gilbert & Cook Inc. Lowers Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Gilbert & Cook Inc. cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,924 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Gilbert & Cook Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,079,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Swiss National Bank grew its position in shares of Alnylam Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after acquiring an additional 1,000 shares during the last quarter. Mutual of America Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 26.7% during the third quarter. Mutual of America Capital Management LLC now owns 1,924 shares of the biopharmaceutical company’s stock worth $529,000 after acquiring an additional 405 shares during the last quarter. Natixis Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $2,751,000. Empowered Funds LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 315.0% during the third quarter. Empowered Funds LLC now owns 7,064 shares of the biopharmaceutical company’s stock worth $1,943,000 after purchasing an additional 5,362 shares during the period. Finally, CIBC Asset Management Inc lifted its holdings in shares of Alnylam Pharmaceuticals by 5.5% during the third quarter. CIBC Asset Management Inc now owns 4,483 shares of the biopharmaceutical company’s stock worth $1,233,000 after purchasing an additional 234 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on ALNY. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 4th. Citigroup increased their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. TD Cowen increased their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Barclays increased their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Finally, The Goldman Sachs Group raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the stock from $198.00 to $370.00 in a report on Friday, August 16th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $294.50.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $235.56 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The firm’s 50-day simple moving average is $274.95 and its 200 day simple moving average is $234.93.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.15 EPS. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. This represents a 16.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.